Samsung Bioepis CEO urges patience as US biosimilar market lags

Posted on by Mila

"Market shaping takes time," the head of the Korean drugmaker told BioPharma Dive, as a few experts call to give up on the copycat biologics altogether.

Source: Healthcare Dive, https://www.healthcaredive.com